RDIF, Brazil agree on production of Russian coronavirus vaccine
MOSCOW, Aug 13 (PRIME) -- The Russian Direct Investment Fund (RDIF) and Brazil’s Parana State agreed on cooperation in production and distribution of the Sputnik V coronavirus vaccine, the RDIF said in a statement late on Wednesday.
“As part of the strategic cooperation agreement, RDIF together with pharmaceutical companies in the state of Parana will organize the production of the ‘Sputnik V’ vaccine and its distribution in Brazil and other Latin American countries. In the near future, RDIF and the Gamaleya National Research Institute of Epidemiology and Microbiology are ready to provide the Parana State Institute of Technology (Tecpar) with the results of the clinical trials of the vaccine and technological protocols of its production,” the statement read.
“The nations of Latin America are now experiencing a difficult situation due to the spread of the coronavirus. We are seeing strong interest from our Brazilian partners in learning from Russia’s experience in the fight against coronavirus, including information related to the first registered coronavirus vaccine in the world,” the RDIF said quoting CEO Kirill Dmitriev.
Brazil is one of five key countries that are ready to support production of the vaccine. The RDIF is looking forward to the approval of the vaccine by Brazilian authorities, Dmitriev said.
The Healthcare Ministry registered the world’s first coronavirus vaccine on August 11. Third stage of clinical trials started on Wednesday. At first, the Gamaleya institute and pharmaceutical company Binnopharm will produce the vaccine, but R-Pharm and Generium will soon join them. Multi-industry holding Sistema said that Binnopharm’s capacities allow it to produce 1.5 million doses of the vaccine per year, and that it planned to start mass production until the end of 2020.